The latest price target for Ventyx Biosciences (NASDAQ:VTYX) was reported by Canaccord Genuity on November 7, 2025. The analyst firm set a price target for $16.00 expecting VTYX to rise to within 12 months (a possible 93.70% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Ventyx Biosciences (NASDAQ:VTYX) was provided by Canaccord Genuity, and Ventyx Biosciences maintained their buy rating.

The last upgrade for Ventyx Biosciences Inc happened on November 5, 2025 when HC Wainwright & Co. raised their price target to $18. HC Wainwright & Co. previously had a neutral for Ventyx Biosciences Inc.

The last downgrade for Ventyx Biosciences Inc happened on November 10, 2023 when Evercore ISI Group changed their price target from $43 to $5 for Ventyx Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ventyx Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ventyx Biosciences was filed on November 7, 2025 so you should expect the next rating to be made available sometime around November 7, 2026.

While ratings are subjective and will change, the latest Ventyx Biosciences (VTYX) rating was a maintained with a price target of $14.00 to $16.00. The current price Ventyx Biosciences (VTYX) is trading at is $8.26, which is out of the analyst’s predicted range.